1,363
Participants
Start Date
October 22, 2015
Primary Completion Date
February 21, 2017
Study Completion Date
February 21, 2017
Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1
0.5 milliliter (mL), Intramuscular
Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2
0.5 mL, Intramuscular
Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3
0.5 mL, Intramuscular
Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4
0.5 mL, Intramuscular
Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed
0.5 mL, Intramuscular
Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine
0.5 mL, Intramuscular
Rochester
Erie
Mt. Pleasant
DeLand
Orlando
Miami
Birmingham
Nashville
Bardstown
Nicholasville
Cleveland
Lincoln
Jonesboro
Fayetteville
Meridian
Salt Lake City
Salt Lake City
Albuquerque
Las Vegas
San Diego
Sanofi Pasteur, a Sanofi Company
INDUSTRY